← 返回

黑色素瘤的免疫治疗:进展、缺陷和未来展望

英文原题:Immunotherapy in melanoma: advances, pitfalls, and future perspectives.

查看英文原题

Immunotherapy in melanoma: advances, pitfalls, and future perspectives.

PubMed 2024/06/28(内容时间) Front Mol Biosci Q2 · IF 4.4(JCR 2025)

分数与星级只用于站内排序 —— 不代表疗效、安全性或个人适用性。

中文摘要

皮肤黑色素瘤是皮肤癌中最致命、最具侵袭性的形式,因其具有高度转移能力。在过去几十年中,随着靶向治疗和免疫治疗的出现,这类恶性肿瘤的管理经历了重大变革,极大地改善了患者的生活质量和生存期。然而,由于副作用和耐药机制的发展,缓解率仍不尽如人意。在此背景下,肿瘤微环境已成为影响免疫治疗应答性和疗效的一个因素,对其与免疫系统相互作用的研究提供了新的有前景的临床策略。本综述通过分析当前黑色素瘤治疗中可用的免疫治疗策略的积极方面以及那些需要进一步改进的方面,对其进行了简要概述。事实上,更好地理解黑色素瘤细胞免疫逃逸所涉及的机制,特别是关注肿瘤微环境的作用,可能为改进当前疗法和识别新的预测性生物标志物提供基础。

展开英文摘要原文

Cutaneous melanoma is the deadliest and most aggressive form of skin cancer owing to its high capacity for metastasis. Over the past few decades, the management of this type of malignancy has undergone a significant revolution with the advent of both targeted therapies and immunotherapy, which have greatly improved patient quality of life and survival. Nevertheless, the response rates are still unsatisfactory for the presence of side effects and development of resistance mechanisms.

In this context, tumor microenvironment has emerged as a factor affecting the responsiveness and efficacy of immunotherapy, and the study of its interplay with the immune system has offered new promising clinical strategies. This review provides a brief overview of the currently available immunotherapeutic strategies for melanoma treatment by analyzing both the positive aspects and those that require further improvement.

Indeed, a better understanding of the mechanisms involved in the immune evasion of melanoma cells, with particular attention on the role of the tumor microenvironment, could provide the basis for improving current therapies and identifying new predictive biomarkers.

论文信息

作者
Sorino C、Iezzi S、Ciuffreda L、Falcone I
单位
SAFU, Department of Research, Advanced Diagnostics, and Technological Innovation, IRCCS-Regina Elena National Cancer Institute, Rome, Italy.United States
文献类型
综述
期刊
Frontiers in molecular biosciences2024
原文标识
PubMed 39086722 · DOI 10.3389/fmolb.2024.1403021